UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 206

Sortiert nach

Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2

PloS one, 2021-03, Vol.16 (3), p.e0248348-e0248348

2021

Link zum Volltext

Verfügbarkeit prüfen

Effects of N-glycan modifications on spike expression, virus infectivity, and neutralization sensitivity in ancestral compared to Omicron SARS-CoV-2 variants

PLoS pathogens, 2023-11, Vol.19 (11), p.e1011788-e1011788

2023

Link zum Volltext

Verfügbarkeit prüfen

D-dimer and CoV-2 spike-immune complexes contribute to the production of PGE2 and proinflammatory cytokines in monocytes

PLoS pathogens, 2022-04, Vol.18 (4), p.e1010468-e1010468

2022

Link zum Volltext

Verfügbarkeit prüfen

Determination of influenza B identity and potency in quadrivalent inactivated influenza vaccines using lineage-specific monoclonal antibodies

PloS one, 2017-04, Vol.12 (4), p.e0175733-e0175733

2017

Link zum Volltext

Verfügbarkeit prüfen

SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic Activity

Viruses, 2021-12, Vol.13 (12), p.2485

2021

Link zum Volltext

Verfügbarkeit prüfen

Glycosylation of Residue 141 of Subtype H7 Influenza A Hemagglutinin (HA) Affects HA-Pseudovirus Infectivity and Sensitivity to Site A Neutralizing Antibodies

PloS one, 2016-02, Vol.11 (2), p.e0149149-e0149149

2016

Link zum Volltext

Verfügbarkeit prüfen

Neutralizing Antibodies Targeting the Conserved Stem Region of Influenza Hemagglutinin

Vaccines (Basel), 2020-07, Vol.8 (3), p.382

2020

Link zum Volltext

Verfügbarkeit prüfen

Neutralizing and protective murine monoclonal antibodies to the hemagglutinin of influenza H5 clades 2.3.2.1 and 2.3.4.4

Influenza and other respiratory viruses, 2023-05, Vol.17 (5), p.e13152-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

Cross-neutralizing antibodies to pandemic 2009 H1N1 and recent seasonal H1N1 influenza A strains influenced by a mutation in hemagglutinin subunit 2

PLoS pathogens, 2011-06, Vol.7 (6), p.e1002081-e1002081

2011

Link zum Volltext

Verfügbarkeit prüfen

Bivalent Coronavirus Disease 2019 Vaccine Antibody Responses to Omicron Variants Suggest That Responses to Divergent Variants Would Be Improved With Matched Vaccine Antigens

The Journal of infectious diseases, 2023-08, Vol.228 (4), p.439-443

2023

Link zum Volltext

Verfügbarkeit prüfen

Selection with a Peptide Fusion Inhibitor Corresponding to the First Heptad Repeat of HIV-1 gp41 Identifies Two Genetic Pathways Conferring Cross-Resistance to Peptide Fusion Inhibitors Corresponding to the First and Second Heptad Repeats (HR1 and HR2) of gp41

Journal of Virology, 2011-12, Vol.85 (24), p.12929-12938

2011

Link zum Volltext

Verfügbarkeit prüfen

Immunogens Modeling a Fusion-Intermediate Conformation of gp41 Elicit Antibodies to the Membrane Proximal External Region of the HIV Envelope Glycoprotein

PloS one, 2015-06, Vol.10 (6), p.e0128562-e0128562

2015

Link zum Volltext

Verfügbarkeit prüfen

Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors

Viruses, 2012-12, Vol.4 (12), p.3859-3911

2012

Link zum Volltext

Verfügbarkeit prüfen

HIV-1 gp41 Residues Modulate CD4-Induced Conformational Changes in the Envelope Glycoprotein and Evolution of a Relaxed Conformation of gp120

Journal of virology, 2018-08, Vol.92 (16)

2018

Link zum Volltext

Verfügbarkeit prüfen

Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants

Journal of virology, 2022-09, Vol.96 (17), p.e0114022-e0114022

2022

Link zum Volltext

Verfügbarkeit prüfen

Peptides Trap the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Fusion Intermediate at Two Sites

Journal of Virology, 2003-02, Vol.77 (3), p.1666-1671

2003

Link zum Volltext

Verfügbarkeit prüfen

Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects

Journal of virology, 2022-01, Vol.96 (1), p.e0111021

2022

Link zum Volltext

Verfügbarkeit prüfen

A mutation in the receptor binding site enhances infectivity of 2009 H1N1 influenza hemagglutinin pseudotypes without changing antigenicity

Virology (New York, N.Y.), 2010-11, Vol.407 (2), p.374-380

2010

Link zum Volltext

Verfügbarkeit prüfen

Dissection of Human Immunodeficiency Virus Type 1 Entry with Neutralizing Antibodies to gp41 Fusion Intermediates

Journal of Virology, 2002-07, Vol.76 (13), p.6780-6790

2002

Link zum Volltext

Verfügbarkeit prüfen

Neutralizing and Neuraminidase Antibodies Correlate With Protection Against Influenza During a Late Season A/H3N2 Outbreak Among Unvaccinated Military Recruits

Clinical infectious diseases, 2020-12, Vol.71 (12), p.3096-3102

2020

Link zum Volltext

Verfügbarkeit prüfen

Intermonomer Interactions in Hemagglutinin Subunits HA1 and HA2 Affecting Hemagglutinin Stability and Influenza Virus Infectivity

Journal of virology, 2015-10, Vol.89 (20), p.10602-10611

2015

Link zum Volltext

Verfügbarkeit prüfen

Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting

The lancet HIV, 2019-04, Vol.6 (4), p.e259-e268

2019

Link zum Volltext

Verfügbarkeit prüfen

Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses

Journal of virology, 2019-06, Vol.93 (11)

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 206

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(191)
Mit Volltextzugriff
(181)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(157)
Life Sciences & Biomedicine
(141)
Humans
(133)
Female
(56)
Biological And Medical Sciences
(49)
Male
(41)
Medical Sciences
(35)
Virology
(35)
Adult
(32)
Microbiology
(27)
Middle Aged
(26)
Animals
(25)
Immunology
(24)
Infectious Diseases
(19)
Aged
(18)
Cell Line
(14)
Child
(14)
Fundamental And Applied Biological Sciences. Psychology
(14)
Health Aspects
(14)
Antibodies
(13)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2

Effects of N-glycan modifications on spike expression, virus infectivity, and neutralization sensitivity in ancestral compared to Omicron SARS-CoV-2 variants

D-dimer and CoV-2 spike-immune complexes contribute to the production of PGE2 and proinflammatory cytokines in monocytes

Determination of influenza B identity and potency in quadrivalent inactivated influenza vaccines using lineage-specific monoclonal antibodies

SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic Activity

Glycosylation of Residue 141 of Subtype H7 Influenza A Hemagglutinin (HA) Affects HA-Pseudovirus Infectivity and Sensitivity to Site A Neutralizing Antibodies

Neutralizing Antibodies Targeting the Conserved Stem Region of Influenza Hemagglutinin

Neutralizing and protective murine monoclonal antibodies to the hemagglutinin of influenza H5 clades 2.3.2.1 and 2.3.4.4

Cross-neutralizing antibodies to pandemic 2009 H1N1 and recent seasonal H1N1 influenza A strains influenced by a mutation in hemagglutinin subunit 2

Bivalent Coronavirus Disease 2019 Vaccine Antibody Responses to Omicron Variants Suggest That Responses to Divergent Variants Would Be Improved With Matched Vaccine Antigens

Selection with a Peptide Fusion Inhibitor Corresponding to the First Heptad Repeat of HIV-1 gp41 Identifies Two Genetic Pathways Conferring Cross-Resistance to Peptide Fusion Inhibitors Corresponding to the First and Second Heptad Repeats (HR1 and HR2) of gp41

Immunogens Modeling a Fusion-Intermediate Conformation of gp41 Elicit Antibodies to the Membrane Proximal External Region of the HIV Envelope Glycoprotein

Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors

HIV-1 gp41 Residues Modulate CD4-Induced Conformational Changes in the Envelope Glycoprotein and Evolution of a Relaxed Conformation of gp120

Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants

Peptides Trap the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Fusion Intermediate at Two Sites

Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects

A mutation in the receptor binding site enhances infectivity of 2009 H1N1 influenza hemagglutinin pseudotypes without changing antigenicity

SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum but evades most convalescent serum and therapeutic antibodies

Dissection of Human Immunodeficiency Virus Type 1 Entry with Neutralizing Antibodies to gp41 Fusion Intermediates

Neutralizing and Neuraminidase Antibodies Correlate With Protection Against Influenza During a Late Season A/H3N2 Outbreak Among Unvaccinated Military Recruits

Intermonomer Interactions in Hemagglutinin Subunits HA1 and HA2 Affecting Hemagglutinin Stability and Influenza Virus Infectivity

Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting

Comparison of A(H3N2) Neutralizing Antibody Responses Elicited by 2018–2019 Season Quadrivalent Influenza Vaccines Derived from Eggs, Cells, and Recombinant Hemagglutinin

Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses

Suchergebnisse filtern